Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 2/20 | 0.72 |
| ▸ | GAA | P10253 | 1/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.67 |
| ▸ | MAPT | P10636 | 6/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.65 |
| ▸ | TSHR | P16473 | 2/20 | 0.65 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.65 |
| ▸ | LMNA | P02545 | 2/20 | 0.65 |
| ▸ | HPGD | P15428 | 1/20 | 0.65 |
| ▸ | ATM | Q13315 | 1/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.64 |
| ▸ | MEN1 | O00255 | 6/20 | 0.64 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.62 |
| ▸ | HTT | P42858 | 1/20 | 0.62 |
| ▸ | PPARG | P37231 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1353257 | 0.87 | TP53 (0.68) | TP53GAAALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL14363413 | 0.84 | MEN1 (0.62) | TP53GAAALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL28894148 | 0.84 | TP53 (1.00) | TP53GAAALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL11620489 | 0.84 | KMT2A (0.72) | TP53GAAALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL15643495 | 0.84 | ALDH1A1 (0.56) | TP53GAAALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL19427718 | 0.83 | MAPT (0.79) | TP53GAAALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL2269427 | 0.83 | GAA (0.62) | TP53GAAALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL29440796 | 0.82 | MEN1 (0.70) | TP53GAAALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL29440795 | 0.82 | MEN1 (0.70) | TP53GAAALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL7881068 | 0.82 | ALDH1A1 (0.57) | TP53GAAALDH1A1SMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7531564-B2 | Substituted benzoxazoles as estrogenic agents | WYETH (US) | 2009-05-12 | — | — | US | disclosed |
| EP-1982713-A2 | Substituted benzoxazoles and analogues as estrogenic agents | Wyeth (US) | 2008-10-22 | — | — | EP | disclosed |
| US-20080255057-A1 | PRODRUG SUBSTITUTED BENZOXAZOLES AS ESTROGENIC AGENTS | WYETH (US) | 2008-10-16 | — | — | US | disclosed |
| US-20070167503-A1 | Substituted benzoxazoles as estrogenic agents | WYETH (US) | 2007-07-19 | — | — | US | disclosed |
| US-7148247-B2 | Substituted benzoxazoles as estrogenic agents | WYETH (US) | 2006-12-12 | — | — | US | disclosed |
| US-7129258-B2 | Substituted benzoxazoles as estrogenic agents | WYETH (US) | 2006-10-31 | — | — | US | disclosed |
| US-20060046968-A1 | Prodrug substituted benzoxazoles as estrogenic agents | WYETH (US) | 2006-03-02 | — | — | US | disclosed |
| US-20050239851-A1 | Substituted benzoxazoles as estrogenic agents | WYETH (US) | 2005-10-27 | — | — | US | disclosed |
| US-20050080117-A1 | Substituted benzoxazoles as estrogenic agents | WYETH (US) | 2005-04-14 | — | — | US | disclosed |
| US-6794403-B2 | FOR TREATING OR INHIBITING INFLAMMATORY BOWEL DISEASE, CROHN'S DISEASE, ULCERATIVE PROCTITIS OR COLITIS PROSTATIC HYPERTROPHY, UTERINE LEIOMYOMAS, BREAST CANCER, ENDOMETRIAL CANCER, CARDIOVASCULAR DISEASE, ALZHEIMER'S DISEASE | WYETH | 2004-09-21 | — | — | US | disclosed |
| US-20030199562-A1 | Substituted benzoxazoles as estrogenic agents | WYETH | 2003-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255057-A1 | PRODRUG SUBSTITUTED BENZOXAZOLES AS ESTROGENIC AGENTS | ESR1, CYP19A1, ESR2 | TP53 764/4885GAA 3710/4885ALDH1A1 818/4885 |
| US-20050239851-A1 | Substituted benzoxazoles as estrogenic agents | ESR1, ESR2, ESRRA | TP53 1802/4885GAA 4366/4885ALDH1A1 1038/4885 |
| US-20050080117-A1 | Substituted benzoxazoles as estrogenic agents | ESR1, ESR2, ESRRA | TP53 1802/4885GAA 4366/4885ALDH1A1 1038/4885 |
| US-20030199562-A1 | Substituted benzoxazoles as estrogenic agents | ESR1, ESR2, ESRRA | TP53 2379/4885GAA 4332/4885ALDH1A1 875/4885 |
| US-20070167503-A1 | Substituted benzoxazoles as estrogenic agents | ESR1, ESR2, ESRRA | TP53 1802/4885GAA 4366/4885ALDH1A1 1038/4885 |
| US-20060046968-A1 | Prodrug substituted benzoxazoles as estrogenic agents | ESR1, CYP19A1, ESR2 | TP53 764/4885GAA 3710/4885ALDH1A1 818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.